Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Carcinog ; 63(4): 589-600, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38197430

ABSTRACT

Prostate cancer (PCa) is the second most common cancer type among American men and it is estimated that in 2023, 34,700 men will die from PCa. Since it can take a considerable amount of time for the disease to progress to clinically evident cancer, there is ample opportunity for effective chemopreventive strategies to be applied for the successful management of PCa progression. In the current study, we have developed a two-tiered metabolomics-based screen to identify synergistic combinations of phytochemicals for PCa chemoprevention. This involves an initial screen for ATP depletion in PCa cells followed by a targeted screen for blocking glutamine uptake in the same cells. One of the phytochemical combinations (enoxolone [ENO] + silibinin [SIL]), identified via this screen, was examined for effects on PCa cell survival, oncogenic signaling and tumor growth in vivo. This combination was found to synergistically reduce cell survival, colony formation and cell cycle progression of PCa cell lines to a greater extent than either agent alone. The combination of ENO and SIL also synergistically reduced tumor growth when administered ad libitum through the diet in a HMVP2 allograft PCa tumor model. Treatment with the combination also significantly reduced STAT3 and mTORC1 signaling pathways in mouse and human PCa cells while significantly reducing levels of critical cell cycle regulatory proteins, contributing to the synergistic inhibition of tumor growth observed. Collectively, the current results demonstrate a novel approach to identifying synergistic combinations of phytochemicals for chemoprevention of PCa and possibly other cancers.


Subject(s)
Glycyrrhetinic Acid , Neoplasms, Second Primary , Prostatic Neoplasms , Male , Humans , Animals , Mice , Early Detection of Cancer , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/prevention & control , Cell Cycle Proteins , Cell Line , Cell Survival , Cell Line, Tumor
2.
J Exp Clin Cancer Res ; 42(1): 119, 2023 May 11.
Article in English | MEDLINE | ID: mdl-37170264

ABSTRACT

BACKGROUND: Prostate Cancer (PCa) represents one of the most commonly diagnosed neoplasms in men and is associated with significant morbidity and mortality. Therapy resistance and significant side effects of current treatment strategies indicate the need for more effective agents to treat both androgen-dependent and androgen-independent PCa. In earlier studies, we demonstrated that depletion of L-cysteine/cystine with an engineered human enzyme, Cyst(e)inase, increased intracellular ROS levels and inhibited PCa growth in vitro and in vivo. The current study was conducted to further explore the mechanisms and potential combinatorial approaches with Cyst(e)inase for treatment of PCa. METHODS: DNA single strand breaks and clustered oxidative DNA damage were evaluated by alkaline comet assay and pulsed field gel electrophoresis, respectively. Neutral comet assay and immunofluorescence staining was used to measure DNA double strand breaks. Cell survival and reactive oxygen species level were measured by crystal violet assay and DCFDA staining, respectively. Western blot was used to determine protein expression. FACS analyses were preformed for immune cell phenotyping. Allograft and xenograft tumor models were used for assessing effects on tumor growth. RESULTS: PCa cells treated with Cyst(e)inase lead to DNA single and double strand breaks resulted from clustered oxidative DNA damage (SSBs and DSBs). Cyst(e)inase in combination with Auranofin, a thioredoxin reductase inhibitor, further increased intracellular ROS and DNA DSBs and synergistically inhibited PCa cell growth in vitro and in vivo. A combination of Cyst(e)inase with a PARP inhibitor (Olaparib) also increased DNA DSBs and synergistically inhibited PCa cell growth in vitro and in vivo without additional ROS induction. Knockdown of BRCA2 in PCa cells increased DSBs and enhanced sensitivity to Cyst(e)inase. Finally, Cyst(e)inase treatment altered tumor immune infiltrates and PD-L1 expression and sensitized PCa cells to anti-PD-L1 treatment. CONCLUSIONS: The current results demonstrate the importance of oxidative DNA damage either alone or in combination for Cyst(e)inase-induced anticancer activity. Furthermore, cysteine/cystine depletion alters the tumor immune landscape favoring enhanced immune checkpoint inhibition targeting PD-L1. Thus, combinatorial approaches with Cyst(e)inase could lead to novel therapeutic strategies for PCa.


Subject(s)
Cysts , Prostatic Neoplasms , Male , Humans , Cysteine/pharmacology , Cysteine/therapeutic use , Immune Checkpoint Inhibitors/therapeutic use , Reactive Oxygen Species/metabolism , Cystine/genetics , Cystine/therapeutic use , Androgens , Cell Line, Tumor , DNA Damage , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , DNA , Cysts/drug therapy
3.
iScience ; 25(5): 104221, 2022 May 20.
Article in English | MEDLINE | ID: mdl-35494234

ABSTRACT

Drugs used in combination can synergize to increase efficacy, decrease toxicity, and prevent drug resistance. While conventional high-throughput screens that rely on univariate data are incredibly valuable to identify promising drug candidates, phenotypic screening methodologies could be beneficial to provide deep insight into the molecular response of drug combination with a likelihood of improved clinical outcomes. We developed a high-content metabolomics drug screening platform using stable isotope-tracer direct-infusion mass spectrometry that informs an algorithm to determine synergy from multivariate phenomics data. Using a cancer drug library, we validated the drug screening, integrating isotope-enriched metabolomics data and computational data mining, on a panel of prostate cell lines and verified the synergy between CB-839 and docetaxel both in vitro (three-dimensional model) and in vivo. The proposed unbiased metabolomics screening platform can be used to rapidly generate phenotype-informed datasets and quantify synergy for combinatorial drug discovery.

4.
J Environ Manage ; 112: 137-48, 2012 Dec 15.
Article in English | MEDLINE | ID: mdl-22898706

ABSTRACT

As a tropical archipelagic nation, the Philippines is particularly susceptible to coastal hazards, which are likely to be exacerbated by climate change. To improve coastal hazard management and adaptation planning, it is imperative that climate information be provided at relevant scales and that decision-makers understand the causes and nature of risk in their constituencies. Focusing on a municipality in the Central Philippines, this study examines local meteorological information and explores household perceptions of climate change and coastal hazard risk. First, meteorological data and local perceptions of changing climate conditions are assessed. Perceived changes in climate include an increase in rainfall and rainfall variability, an increase in intensity and frequency of storm events and sea level rise. Second, factors affecting climate change perceptions and perceived risk from coastal hazards are determined through statistical analysis. Factors tested include social status, economic standing, resource dependency and spatial location. Results indicate that perceived risk to coastal hazards is most affected by households' spatial location and resource dependency, rather than socio-economic conditions. However, important differences exist based on the type of hazard and nature of risk being measured. Resource dependency variables are more significant in determining perceived risk from coastal erosion and sea level rise than flood events. Spatial location is most significant in determining households' perceived risk to their household assets, but not perceived risk to their livelihood.


Subject(s)
Climate Change , Seawater , Philippines
SELECTION OF CITATIONS
SEARCH DETAIL
...